Merck, Inc.
🇵🇭Philippines
Protocol for Eslax Intravenous Drug Use Investigation (Study P06082)
- First Posted Date
- 2009-05-14
- Last Posted Date
- 2015-10-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 3969
- Registration Number
- NCT00902070
Magnetic Resonance Elastography for Assessment of Liver Fibrosis (MK-0000-132)(COMPLETED)
Phase 1
Completed
- Conditions
- Liver FibrosisHepatitis C Virus
- Interventions
- Procedure: MRE
- First Posted Date
- 2009-05-11
- Last Posted Date
- 2015-08-25
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 10
- Registration Number
- NCT00896233
Study to Evaluate Different Regimens of Vaniprevir (MK7009) for the Treatment of Chronic Genotype 1 Hepatitis C Virus Infection in Treatment-naive Patients (MK-7009-019)(WITHDRAWN)
Phase 2
Withdrawn
- Conditions
- Chronic Genotype 1 Hepatitis C Virus Infection
- Interventions
- First Posted Date
- 2009-05-08
- Last Posted Date
- 2015-10-22
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Registration Number
- NCT00895882
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Four-Week Treatment Period (P08638)
Phase 2
Completed
- Conditions
- Blepharitis
- Interventions
- Drug: Azithromycin ophthalmic solution, 1%Drug: Placebo
- First Posted Date
- 2009-05-07
- Last Posted Date
- 2013-11-21
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 314
- Registration Number
- NCT00894530
- Locations
- 🇺🇸
Schwartz Laser Eye Center, Scottsdale, Arizona, United States
🇺🇸Eastern Maine Medical Center, Bangor, Maine, United States
🇺🇸Total Eye Care, PA, Memphis, Tennessee, United States
A Study of Safety, Tolerability and Immunogenicity of a 1-Dose Regimen of MRKAd5 HIV-1 Gag Vaccine Versus the ALVAC_HIV Vaccine (V520-019)
Phase 1
Completed
- Conditions
- HIV-1 Infection
- Interventions
- Biological: V520
- First Posted Date
- 2009-05-06
- Last Posted Date
- 2015-05-28
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 250
- Registration Number
- NCT00894114
The Effects of Azithromycin Ophthalmic Solution, 1% Versus Placebo in Subjects With Blepharitis During a Two-Week Treatment Period
Phase 2
Completed
- Conditions
- Blepharitis
- Interventions
- Drug: Azithromycin ophthalmic solution, 1%Drug: Placebo
- First Posted Date
- 2009-05-05
- Last Posted Date
- 2011-09-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 313
- Registration Number
- NCT00892970
- Locations
- 🇺🇸
Ophthalmology Associates, St. Louis, Missouri, United States
🇺🇸Wilmer Eye Institute, Johns Hopkins Hospital, Baltimor, Maryland, United States
🇺🇸Milton Hom, OD, Azusa, California, United States
MK0954 Versus Placebo for Treatment of Mild to Moderate Hypertension
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2009-07-09
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 428
- Registration Number
- NCT00888355
A Method to Evaluate Glucose-Dependent Insulin Secretion in Healthy Males (MK-0431-179)
- First Posted Date
- 2009-04-27
- Last Posted Date
- 2018-06-26
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 12
- Registration Number
- NCT00888238
BOLD Functional Magnetic Resonance Imaging (fMRI) and Cerebral Blood Flow Measurements as Biomarkers for Cognition Enhancing Drugs (3134-006)
- First Posted Date
- 2009-04-24
- Last Posted Date
- 2015-07-30
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 32
- Registration Number
- NCT00887601
A Study to Investigate the Antihypertensive Efficacy of MK0954
- First Posted Date
- 2009-04-23
- Last Posted Date
- 2009-07-14
- Lead Sponsor
- Merck Sharp & Dohme LLC
- Target Recruit Count
- 366
- Registration Number
- NCT00887250
© Copyright 2025. All Rights Reserved by MedPath